Paris (France). June 1st. 2023. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory conditions, announced today the publication of the results of two phase 2 clinical studies in the The Lancet Respiratory Medicine and in eClinicalMedicine. The first article presents the ASTONISH Phase
IBD Innovate 2023 – April 26. 2023 (New York) – Inotrem welcomes you at IBD Innovate 2023, the annual one-day event organized by the Crohn’s & Colitis Foundation. Marc Derive, Inotrem’s Co-Founder & Chief Scientific Officer, is excited to share his presentation: “The Therapeutic Potential of Targeting TREM-1 and First
ISICEM. March 21-24, 2023. Brussels. Inotrem will be attending the 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM) Symposium in Brussels. Since its first edition in 1980, ISICEM has become one of the largest meetings in its field, attracting more than 6200 participants from countries worldwide. This four-day
We are thrilled and honored to have been chosen for the 3rd year in a row to join the French Tech 120, a government-backed support program dedicated to the most successful and fast-growing start-ups of the French #tech ecosystem. French Tech 120 Program Class of 2023 is the Class with
41st Annual J.P. Morgan HEALTHCARE CONFERENCE. January 9—12, 2023. San Francisco, CA. Inotrem is pleased to announce its participation in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Sven Zimmermann, CEO, is scheduled to present on January 11, 2023 at 11:00 am Pacific Time results from the 2
Paris (France), January 9th. 2023. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received funding from the Crohn’s & Colitis Foundation’s IBD Ventures under a program to accelerate research and development that aim to improve the quality of life
Inotrem will attend Immunotherapies & Innovations For Infectious Diseases 6th Congress. It is looking forward to meeting you at its lecture presenting the results of its last two clinical trials, ASTONISH and ESSENTIAL, targeting TREM-1 for the treatment of Septic Shock and Critically-Ill COVID-19 patients.
Paris (France), October 25. 2022. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, announced today at the European Society of Intensive Care Medicine’s Annual Congress, held in Paris, positive results for ESSENTIAL, its Phase II clinical trial in COVID-19 patients hospitalized in
Inotrem is pleased to attend the European Society of Intensive Care Medicine’s 35th Annual Congress in Paris where it will be holding a Symposium on “Targeting TREM-1 to Manage Life-Threatening Immune Disorders Caused by Severe Infections”
Inotrem welcomes you at the Symposium it will be holding during ISICIP 2022 on “Correcting Severe Immune Dysregulations in Sever Infections. The role of the TREM-1 Pathway. Applications in Septic Shock and COVID-10”.
Paris (France), October 13, 2022. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, disclosed for the first time today at the International Sepsis Forum held in Barcelona the results for its Phase IIb ASTONISH clinical trial in septic shock patients.
Paris (France), May 31. 2022. Inotrem, an advanced clinical stage biotech company developing TREM- 1 targeting immunotherapies for acute and chronic inflammatory syndromes, announced today the appointment of Luke Beshar as Chairman of its Board of Directors, effective May 25, 2022. Mr. Beshar succeeds Thierry Hercend who served as Chairman
BioEquity Europe, Milan, May 16-18, 2022. Inotrem is pleased to attend BioEquity Europe that will take place in Milan on May 16-18, 2022
LIVES 40, Madrid, May 12-14, 2022. The European Society of Intensive Care Medicine (ESICM) celebrates its 40th anniversary with a three-days event in Madrid.
Paris (France), April 14th 2022. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today a R&D collaboration agreement with the Crohn’s & Colitis Foundation to support the development of a new therapeutic approach in IBD.
Paris, March 17, 2022. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today the appointment of Laurent Vincens as Chief Technology Officer and Head of Manufacturing. The newly created position comes as the company is rapidly advancing its TREM-1 pathway focused
March 1-2. 2022, Sachs European Life-Science CEO Forum (on line). Inotrem will participate to the 15th Annual European Life Sciences CEO Forum (ELSF) that will take place on the 1st-2nd of March 2022 and is part of the Sachs Spring Life Sciences Week. Inotrem is pleased to participate to this global bio-pharma industry event and, through
Geneva, Switzerland, and Paris, France, January 19, 2022 – Selexis SA, a JSR Life Sciences company, and Inotrem SA, an advanced clinical-stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, have signed a service agreement to develop the cell line for Inotrem’s antibody-based candidate to address chronic
Paris, France. November 9, 2021. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies targeting the TREM-1 pathway, announced today the appointment of Dr. Gregory Meiffren as Project Director for its Antibody-based R&D Program. The creation of this position comes at a time of significant growth for Inotrem as
November 15-16. 2021. Lyon, France. Inotrem is pleased to participate to the fifth edition of the Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2021). Fostering quality interactions between hundreds of pharmaceutical companies, research labs, service providers, technology developers, and clinicians, I4ID has become a central event contributing to the development of
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS
Follow us LinkedIn
Inotrem 2023 – Legal notices
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS – Follow us LinkedIn
Inotrem 2023 – Legal notices